Abstract: This disclosure relates to certain pyrrolopyridone compounds. Certain compounds of the disclosure are potent and selective Bromodomain and Extra-Terminal (BET) inhibitors. The disclosure also relates to pharmaceutically acceptable salts of the compounds or N-oxides thereof, methods of treating diseases and disorders using the compounds, salts, or N-oxides thereof and compositions comprising the compounds salts or N-oxides thereof. The disclosure additionally relates to methods for the treatment of inflammatory and autoimmune diseases and disorders (e.g., skin diseases and disorders, joint and joint-related diseases and disorders, and fibrosis or fibrosis-associated diseases or disorders) using potent and selective BET inhibitors and formulations comprising the disclosed BET inhibitors.

Abstract: The present disclosure relates to methods for the treatment, amelioration, or prophylaxis of an inflammatory and/or an autoimmune disease or disorder or a disease or disorder related thereto (e.g., wounds, pigmentation or pigmentation related diseases and disorders, joint or joint related diseases and disorders, respiratory or respiratory related diseases or disorders; and fibrosis or fibrosis associated diseases and disorders) using soft BET inhibitors.

Abstract: The present disclosure relates to compositions, including foamable compositions with improved properties, such as those comprising waxes, emollients, foam adjuvants and/or active agents, and methods for preparing and using them.

Abstract: The present disclosure relates to compositions, including foamable compositions with improved properties, such as those comprising waxes, emollients, foam adjuvants and/or active agents, and methods for preparing and using them.

Abstract: The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, vitiligo and eczema.